PHG — Koninklijke Philips N.V. NY Reg

Is PHG overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Overbought As of August 19, 2026

Koninklijke Philips N.V. NY Reg (PHG) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $27.10. The rating moved from Neutral to Overbought on August 8, 2026.

See all overbought Healthcare stocks →

AI analysis

Koninklijke Philips N.V. (PHG) is a large, diversified medical technology company with durable revenue streams from equipment sales, service contracts and software. Financial health has improved via margin‑restoration and cost programs, but near‑term cash flow and earnings remain influenced by legal and regulatory overhang, hospital capex cycles, and FX. Competitive strengths include a sizable installed base, leadership in imaging and monitoring, and early AI/diagnostics initiatives that can expand software and recurring revenue. Key catalysts include stabilization of recall-related liabilities, continued margin progress, and commercial traction for AI-enabled offerings. Main challenges are ongoing litigation/regulatory risk, competitive pressure, and sensitivity to provider spending. Market sentiment in the near term is constructive for growth-oriented names, which could help performance, but geopolitical headlines and regulatory actions could introduce volatility. Reasonable scenarios include modest upside if margin initiatives and software monetization accelerate, or downside pressure if legal costs or hospital budget weakness re‑emerge.

Key factors

  • Large, diversified med‑tech portfolio with leading positions in imaging, patient monitoring, and acute care products
  • Substantial installed base and recurring service/replacement revenue supporting cash flow stability
  • Ongoing product innovation and early AI-enabled imaging and monitoring initiatives that can drive software and service upsell
  • Restructuring and cost‑efficiency programs that aim to restore margins and free cash flow
  • Exposure to diagnostic and screening demand trends which are currently constructive for imaging and lab services
  • Near‑term sensitivity to hospital capital spending and cyclical procedure volumes

Risks

  • Regulatory and litigation overhang from past product issues and potential future recalls, creating cash and reputational risk
  • Intense competition from GE Healthcare, Siemens Healthineers and others, pressuring pricing and share in key segments
  • Hospital and provider capital budget constraints that could delay purchases of high‑ticket equipment
  • FX volatility and macroeconomic weakness in key markets could compress revenue and margins
  • Supply‑chain disruptions or component shortages that affect deliveries and service commitments
  • Slower-than-expected commercial adoption of AI/software offerings or increased regulatory scrutiny of AI in healthcare

See today's live rating, score and targets

Members see the live hourly rating for PHG — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.